BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug

Reuters01-05
BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug

** Shares of drug developer Altimmune ALT.O rise 12.8% to $3.96 premarket

** ALT says U.S. FDA has granted "breakthrough therapy" tag for its experimental drug to treat patients with a type of liver disease

** The drug, pemvidutide, is being tested in patients with metabolic dysfunction-associated steatohepatitis or MASH — a serious liver disease that develops when fat buildup causes inflammation of the organ

** The breakthrough therapy tag is meant to speed up development and review of drugs to treat serious conditions or those with unmet medical needs

** Co says it plans to initiate a late-stage trial evaluating multiple pemvidutide doses over a 52-week treatment period

** In last 12 months, stock down 2.8%

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment